Pediatric Spinal Muscular Atrophy (SMA) China Registry
← catalyst calendarNCT05042921 · readout in 378 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
600actual
Sites
25
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-18 | actual | When the study began enrolling |
| Primary completion | 2027-09-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-02 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscular Atrophy, Spinal
Primary outcome
what the primary-completion date above is the date OFNatural History and Utilization of Disease Modifying Therapy (DMT) Treatments Among Pediatric Chinese Participants With Spinal Muscular Atrophy Linked to Chromosome 5q (5q-SMA)
measured Up to 60 months
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed